Becton Dickinson and Co當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名3/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價203.75。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Becton Dickinson and Co評分
相關信息
行業排名
3 / 208
全市場排名
47 / 4592
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
14
分析師
買入
評級
203.751
目標均價
+7.52%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Becton Dickinson and Co亮點
亮點風險
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
公司代碼BDX
公司Becton Dickinson and Co
CEOPolen (Thomas E)
網址https://www.bd.com/
常見問題
Becton Dickinson and Co(BDX)的當前股價是多少?
Becton Dickinson and Co(BDX)的當前股價是 200.120。
Becton Dickinson and Co 的股票代碼是什麼?
Becton Dickinson and Co的股票代碼是BDX。
Becton Dickinson and Co股票的52週最高點是多少?
Becton Dickinson and Co股票的52週最高點是251.985。
Becton Dickinson and Co股票的52週最低點是多少?
Becton Dickinson and Co股票的52週最低點是162.290。
Becton Dickinson and Co的市值是多少?
Becton Dickinson and Co的市值是57.11B。
Becton Dickinson and Co的淨利潤是多少?
Becton Dickinson and Co的淨利潤為1.68B。
現在Becton Dickinson and Co(BDX)的股票是買入、持有還是賣出?
根據分析師評級,Becton Dickinson and Co(BDX)的總體評級為買入,目標價格為203.751。
Becton Dickinson and Co(BDX)股票的每股收益(EPS TTM)是多少
Becton Dickinson and Co(BDX)股票的每股收益(EPS TTM)是5.834。